Twist Bioscience Key Executives
This section highlights Twist Bioscience's key executives, including their titles and compensation details.
Find Contacts at Twist Bioscience
(Showing 0 of )
Twist Bioscience Earnings
This section highlights Twist Bioscience's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q1 | 2025 | 2025-02-03 | $-0.62 | $-0.53 |
| Read Transcript | Q4 | 2024 | 2024-11-18 | $-0.71 | $-0.59 |
| Read Transcript | Q3 | 2024 | 2024-08-02 | $-0.79 | $-0.86 |
| Read Transcript | Q2 | 2024 | 2024-05-02 | $-0.84 | $-0.79 |
| Read Transcript | Q1 | 2024 | 2024-02-02 | $-0.80 | $-0.75 |
| Read Transcript | Q4 | 2023 | 2023-11-17 | $-0.94 | $-0.81 |
| Read Transcript | Q3 | 2023 | 2023-08-04 | $-1.14 | $-1.01 |
| Read Transcript | Q2 | 2023 | 2023-05-05 | $-1.09 | $-1.06 |
| Read Transcript | Q1 | 2023 | 2023-02-03 | $-1.09 | $-0.74 |
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.
$44.94
Stock Price
$2.68B
Market Cap
923
Employees
South San Francisco, CA
Location
Financial Statements
Access annual & quarterly financial statements for Twist Bioscience, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | September 30, 2024 | September 30, 2023 | September 30, 2022 | September 30, 2021 | September 30, 2020 |
|---|---|---|---|---|---|
| Revenue | $312.97M | $245.11M | $203.56M | $132.33M | $90.10M |
| Cost of Revenue | $179.62M | $155.38M | $119.33M | $80.62M | $61.41M |
| Gross Profit | $133.35M | $89.73M | $84.23M | $51.71M | $28.69M |
| Gross Profit Ratio | 42.61% | 36.60% | 41.38% | 39.10% | 31.85% |
| Research and Development Expenses | $90.85M | $106.89M | $120.31M | $69.07M | $43.01M |
| General and Administrative Expenses | $- | $186.84M | $210.55M | $133.40M | $102.07M |
| Selling and Marketing Expenses | $- | $2.90M | $2.40M | $2.50M | $1.20M |
| Selling General and Administrative Expenses | $218.40M | $189.74M | $212.95M | $135.90M | $103.27M |
| Other Expenses | $44.93M | $10.26M | $-1.09M | $-1.37M | $-182.00K |
| Operating Expenses | $354.18M | $306.89M | $333.26M | $204.97M | $146.27M |
| Cost and Expenses | $533.80M | $462.27M | $452.59M | $285.59M | $207.68M |
| Interest Income | $15.34M | $14.37M | $3.06M | $435.00K | $1.50M |
| Interest Expense | $29.00K | $5.00K | $80.00K | $367.00K | $787.00K |
| Depreciation and Amortization | $31.43M | $29.31M | $36.64M | $11.99M | $6.68M |
| EBITDA | $-176.71M | $-174.15M | $-191.55M | $-143.91M | $-132.09M |
| EBITDA Ratio | -56.46% | -71.05% | -121.36% | -116.52% | -129.04% |
| Operating Income | $-220.83M | $-217.16M | $-249.02M | $-153.26M | $-117.58M |
| Operating Income Ratio | -70.56% | -88.60% | -122.33% | -115.81% | -130.50% |
| Total Other Income Expenses Net | $12.66M | $13.69M | $6.50M | $-1.30M | $530.00K |
| Income Before Tax | $-208.17M | $-203.47M | $-228.27M | $-154.03M | $-139.55M |
| Income Before Tax Ratio | -66.51% | -83.01% | -112.14% | -116.39% | -154.88% |
| Income Tax Expense | $560.00K | $1.15M | $-10.41M | $-1.93M | $382.00K |
| Net Income | $-208.73M | $-204.62M | $-217.86M | $-152.10M | $-139.93M |
| Net Income Ratio | -66.69% | -83.48% | -107.02% | -114.94% | -155.31% |
| EPS | $-3.60 | $-3.60 | $-4.04 | $-3.15 | $-3.57 |
| EPS Diluted | $-3.60 | $-3.60 | $-4.04 | $-3.15 | $-3.57 |
| Weighted Average Shares Outstanding | 58.02M | 56.88M | 53.88M | 48.25M | 39.19M |
| Weighted Average Shares Outstanding Diluted | 58.02M | 56.88M | 53.88M | 48.25M | 39.19M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $88.71M | $84.71M | $81.46M | $75.30M | $71.50M | $66.95M | $63.74M | $60.18M | $54.24M | $57.31M | $56.11M | $48.13M | $42.02M | $37.95M | $35.02M | $31.20M | $28.16M | $32.43M | $21.21M | $19.30M |
| Cost of Revenue | $45.87M | $46.48M | $46.19M | $44.42M | $42.54M | $42.42M | $41.84M | $41.67M | $29.44M | $31.59M | $30.97M | $29.71M | $27.06M | $22.50M | $20.93M | $19.03M | $18.16M | $17.58M | $16.47M | $13.56M |
| Gross Profit | $42.84M | $38.23M | $35.27M | $30.88M | $28.96M | $24.52M | $21.89M | $18.51M | $24.80M | $25.72M | $25.14M | $18.41M | $14.96M | $15.45M | $14.09M | $12.18M | $10.00M | $14.85M | $4.74M | $5.73M |
| Gross Profit Ratio | 48.29% | 45.10% | 43.30% | 41.00% | 40.50% | 36.60% | 34.40% | 30.80% | 45.70% | 44.90% | 44.80% | 38.30% | 35.60% | 40.70% | 40.20% | 39.00% | 35.50% | 45.80% | 22.33% | 29.71% |
| Research and Development Expenses | $21.31M | $21.13M | $22.47M | $24.15M | $23.10M | $23.75M | $24.53M | $27.38M | $31.24M | $29.61M | $36.84M | $31.23M | $22.63M | $19.44M | $19.84M | $15.79M | $14.00M | $11.64M | $10.44M | $10.63M |
| General and Administrative Expenses | $- | $- | $- | $- | $- | $44.49M | $- | $- | $- | $51.76M | $- | $- | $- | $28.79M | $- | $- | $28.79M | $76.08M | $22.49M | $27.19M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $2.90M | $- | $- | $- | $2.40M | $- | $- | $- | $9.45M | $- | $- | $- | $-48.90M | $- | $- |
| Selling General and Administrative Expenses | $56.18M | $53.14M | $56.79M | $55.62M | $52.84M | $47.39M | $46.06M | $53.97M | $42.32M | $54.16M | $53.69M | $54.00M | $51.10M | $38.24M | $34.48M | $34.39M | $28.79M | $27.18M | $22.49M | $27.19M |
| Other Expenses | $- | $- | $44.93M | $-199.00K | $-31.00K | $-245.00K | $41.00K | $-305.00K | $-157.00K | $-461.00K | $-225.00K | $-245.00K | $-156.00K | $-1.06M | $-312.00K | $84.00K | $-77.00K | $-57.00K | $-56.00K | $18.00K |
| Operating Expenses | $77.48M | $74.28M | $124.19M | $79.77M | $75.94M | $71.14M | $70.58M | $81.34M | $73.57M | $83.77M | $90.53M | $85.23M | $73.73M | $57.69M | $54.32M | $50.18M | $42.79M | $38.82M | $32.93M | $37.82M |
| Cost and Expenses | $123.36M | $120.75M | $170.39M | $124.19M | $118.47M | $113.56M | $112.43M | $123.01M | $103.01M | $115.35M | $121.51M | $114.94M | $100.78M | $80.18M | $75.25M | $69.21M | $60.95M | $56.40M | $49.40M | $51.38M |
| Interest Income | $3.24M | $3.62M | $3.66M | $3.94M | $4.12M | $3.89M | $3.97M | $3.46M | $3.04M | $1.93M | $722.00K | $259.00K | $154.00K | $58.00K | $86.00K | $157.00K | $134.00K | $112.00K | $247.00K | $576.00K |
| Interest Expense | $24.00K | $29.00K | $- | $- | $- | $1.00K | $1.00K | $2.00K | $1.00K | $26.00K | $- | $29.00K | $26.00K | $83.00K | $70.00K | $95.00K | $118.00K | $143.00K | $181.00K | $215.00K |
| Depreciation and Amortization | $6.38M | $6.66M | $8.30M | $8.30M | $8.17M | $8.50M | $9.04M | $7.36M | $5.55M | $22.48M | $5.53M | $4.30M | $4.32M | $3.63M | $3.57M | $2.46M | $2.11M | $1.89M | $1.72M | $1.56M |
| EBITDA | $-25.09M | $-28.07M | $-77.08M | $-36.85M | $-34.72M | $-37.96M | $-47.73M | $-51.12M | $-36.20M | $-28.31M | $-55.14M | $-56.48M | $-51.62M | $-37.19M | $-38.77M | $-35.30M | $-30.68M | $-22.02M | $-26.28M | $-29.93M |
| EBITDA Ratio | -28.29% | -33.13% | -94.62% | -53.90% | -48.56% | -64.18% | -70.10% | -99.16% | -84.59% | -98.73% | -115.65% | -130.56% | -139.86% | -113.93% | -115.53% | -113.12% | -116.25% | -73.73% | -132.06% | -163.20% |
| Operating Income | $-34.64M | $-36.04M | $-88.92M | $-48.89M | $-46.98M | $-50.11M | $-60.78M | $-62.83M | $-48.77M | $-58.05M | $-61.16M | $-66.82M | $-55.94M | $-39.81M | $-42.12M | $-38.00M | $-32.79M | $-23.97M | $-28.20M | $-32.09M |
| Operating Income Ratio | -39.05% | -42.55% | -109.15% | -64.92% | -65.70% | -74.85% | -95.36% | -104.41% | -89.90% | -101.29% | -109.00% | -138.83% | -133.13% | -104.90% | -120.28% | -121.79% | -116.45% | -73.90% | -132.96% | -166.27% |
| Total Other Income Expenses Net | $3.15M | $1.29M | $3.54M | $3.74M | $4.09M | $3.65M | $4.01M | $3.16M | $2.88M | $6.05M | $497.00K | $-15.00K | $-28.00K | $-1.09M | $-296.00K | $146.00K | $-61.00K | $-88.00K | $10.00K | $379.00K |
| Income Before Tax | $-31.50M | $-34.75M | $-85.38M | $-45.15M | $-42.89M | $-46.46M | $-56.77M | $-58.48M | $-41.75M | $-50.82M | $-60.67M | $-60.82M | $-55.97M | $-40.90M | $-42.41M | $-37.86M | $-32.85M | $-24.05M | $-28.19M | $-31.71M |
| Income Before Tax Ratio | -35.50% | -41.02% | -104.81% | -59.95% | -59.98% | -69.41% | -89.07% | -97.18% | -76.96% | -88.69% | -108.11% | -126.37% | -133.20% | -107.77% | -121.12% | -121.32% | -116.66% | -74.17% | -132.91% | -164.31% |
| Income Tax Expense | $97.00K | $-96.00K | $191.00K | $345.00K | $120.00K | $-221.00K | $622.00K | $676.00K | $76.00K | $292.00K | $-149.00K | $-149.00K | $-10.40M | $340.00K | $-2.38M | $61.00K | $46.00K | $263.00K | $21.00K | $61.00K |
| Net Income | $-31.59M | $-34.66M | $-85.57M | $-45.49M | $-43.01M | $-46.24M | $-57.40M | $-59.16M | $-41.82M | $-51.12M | $-60.52M | $-60.67M | $-45.56M | $-41.24M | $-40.04M | $-37.92M | $-32.90M | $-24.32M | $-28.21M | $-31.77M |
| Net Income Ratio | -35.61% | -40.91% | -105.04% | -60.41% | -60.15% | -69.08% | -90.05% | -98.30% | -77.10% | -89.20% | -107.85% | -126.06% | -108.44% | -108.67% | -114.33% | -121.52% | -116.83% | -74.98% | -133.01% | -164.63% |
| EPS | $-0.53 | $-0.60 | $-1.47 | $-0.79 | $-0.75 | $-0.81 | $-1.01 | $-1.04 | $-0.74 | $-0.91 | $-1.08 | $-1.13 | $-0.91 | $-0.84 | $-0.82 | $-0.78 | $-0.72 | $-0.55 | $-0.67 | $-0.85 |
| EPS Diluted | $-0.53 | $-0.60 | $-1.47 | $-0.79 | $-0.75 | $-0.81 | $-1.01 | $-1.04 | $-0.74 | $-0.91 | $-1.08 | $-1.13 | $-0.91 | $-0.84 | $-0.82 | $-0.78 | $-0.72 | $-0.54 | $-0.67 | $-0.85 |
| Weighted Average Shares Outstanding | 59.16M | 58.02M | 58.15M | 57.78M | 57.50M | 57.28M | 56.83M | 56.78M | 56.44M | 56.27M | 56.29M | 53.47M | 49.91M | 49.35M | 48.83M | 48.71M | 46.00M | 44.37M | 41.84M | 37.16M |
| Weighted Average Shares Outstanding Diluted | 59.16M | 58.02M | 58.15M | 57.78M | 57.50M | 57.28M | 57.04M | 56.78M | 56.44M | 56.27M | 56.29M | 53.47M | 49.91M | 49.35M | 48.96M | 48.71M | 46.00M | 44.78M | 41.84M | 37.16M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | September 30, 2024 | September 30, 2023 | September 30, 2022 | September 30, 2021 | September 30, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $226.32M | $286.47M | $378.69M | $465.83M | $93.67M |
| Short Term Investments | $50.08M | $49.94M | $126.28M | $12.03M | $196.34M |
| Cash and Short Term Investments | $276.40M | $336.41M | $504.97M | $477.86M | $290.00M |
| Net Receivables | $34.90M | $44.06M | $40.29M | $28.55M | $26.38M |
| Inventory | $24.08M | $32.06M | $39.31M | $31.80M | $12.29M |
| Other Current Assets | $11.40M | $11.72M | $23.83M | $16.57M | $12.41M |
| Total Current Assets | $346.78M | $424.26M | $596.48M | $546.50M | $334.87M |
| Property Plant Equipment Net | $161.35M | $203.36M | $214.39M | $105.70M | $59.16M |
| Goodwill | $85.81M | $85.81M | $85.81M | $22.43M | $1.14M |
| Intangible Assets | $14.48M | $54.48M | $59.74M | $18.26M | $307.00K |
| Goodwill and Intangible Assets | $100.29M | $140.29M | $145.55M | $40.70M | $1.45M |
| Long Term Investments | $- | $- | $1.57M | $1.53M | $579.00K |
| Tax Assets | $- | $- | $-1.57M | $-1.53M | $-579.00K |
| Other Non-Current Assets | $5.91M | $8.49M | $4.96M | $9.20M | $3.40M |
| Total Non-Current Assets | $267.55M | $352.15M | $364.89M | $155.60M | $64.01M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $614.32M | $776.40M | $961.38M | $702.10M | $398.88M |
| Account Payables | $1.63M | $14.05M | $20.09M | $14.90M | $4.83M |
| Short Term Debt | $29.61M | $14.90M | $27.28M | $17.98M | $16.15M |
| Tax Payables | $2.73M | $4.37M | $3.66M | $2.44M | $719.00K |
| Deferred Revenue | $2.13M | $- | $3.48M | $28.76M | $18.85M |
| Other Current Liabilities | $34.91M | $40.00M | $36.15M | $27.73M | $14.33M |
| Total Current Liabilities | $71.01M | $73.32M | $90.66M | $63.05M | $36.03M |
| Long Term Debt | $70.22M | $79.17M | $81.27M | $53.16M | $26.24M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $407.00K | $475.00K | $60.00K | $5.07M | $351.00K |
| Total Non-Current Liabilities | $70.63M | $79.65M | $81.33M | $58.22M | $26.59M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $141.63M | $152.97M | $171.99M | $121.28M | $62.62M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $- | $- | $- | $- | $- |
| Retained Earnings | $-1.24B | $-1.03B | $-828.42M | $-610.55M | $-458.45M |
| Accumulated Other Comprehensive Income Loss | $-522.00K | $-756.00K | $-1.84M | $546.00K | $87.00K |
| Other Total Stockholders Equity | $1.72B | $1.66B | $1.62B | $1.19B | $794.63M |
| Total Stockholders Equity | $472.69M | $623.43M | $789.38M | $580.82M | $336.26M |
| Total Equity | $472.69M | $623.43M | $789.38M | $580.82M | $336.26M |
| Total Liabilities and Stockholders Equity | $614.32M | $776.40M | $961.38M | $702.10M | $398.88M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $614.32M | $776.40M | $961.38M | $702.10M | $398.88M |
| Total Investments | $50.08M | $49.94M | $126.28M | $12.03M | $196.34M |
| Total Debt | $85.03M | $94.07M | $94.91M | $62.92M | $35.98M |
| Net Debt | $-141.29M | $-192.40M | $-283.77M | $-402.91M | $-57.69M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $221.40M | $226.32M | $239.14M | $243.35M | $266.27M | $286.47M | $307.46M | $315.20M | $316.68M | $378.69M | $376.25M | $407.63M | $191.62M | $465.83M | $475.28M | $399.33M | $348.79M | $93.67M | $207.85M | $184.40M |
| Short Term Investments | $49.42M | $50.08M | $50.28M | $49.99M | $44.88M | $49.94M | $49.69M | $72.46M | $122.03M | $126.28M | $151.34M | $166.23M | $110.23M | $12.03M | $44.13M | $156.33M | $238.50M | $196.34M | $103.91M | $45.67M |
| Cash and Short Term Investments | $270.83M | $276.40M | $289.42M | $293.34M | $311.14M | $336.41M | $357.14M | $387.66M | $438.71M | $504.97M | $527.59M | $573.86M | $301.86M | $477.86M | $519.41M | $555.66M | $587.28M | $290.00M | $311.76M | $230.06M |
| Net Receivables | $39.31M | $34.90M | $31.99M | $37.09M | $35.35M | $44.06M | $42.58M | $48.19M | $44.44M | $40.29M | $41.20M | $34.88M | $32.87M | $28.55M | $28.12M | $27.29M | $25.49M | $26.38M | $13.35M | $14.83M |
| Inventory | $23.52M | $24.08M | $28.48M | $30.38M | $30.86M | $32.06M | $36.35M | $39.92M | $44.60M | $39.31M | $43.02M | $44.59M | $40.24M | $31.80M | $21.22M | $15.84M | $13.41M | $12.29M | $13.16M | $10.76M |
| Other Current Assets | $11.65M | $11.40M | $11.94M | $12.16M | $12.87M | $11.72M | $9.46M | $13.50M | $14.12M | $23.83M | $24.62M | $22.10M | $20.07M | $16.57M | $15.72M | $18.43M | $16.48M | $12.41M | $6.31M | $4.55M |
| Total Current Assets | $345.31M | $346.78M | $361.83M | $371.87M | $390.23M | $424.26M | $445.54M | $489.27M | $541.86M | $596.48M | $624.12M | $664.38M | $385.01M | $546.50M | $576.61M | $608.00M | $634.43M | $334.87M | $344.58M | $260.20M |
| Property Plant Equipment Net | $157.14M | $161.35M | $167.62M | $185.00M | $195.32M | $203.36M | $212.81M | $217.21M | $218.61M | $214.39M | $203.18M | $170.03M | $137.16M | $105.70M | $100.67M | $62.97M | $59.48M | $59.16M | $58.93M | $59.12M |
| Goodwill | $85.81M | $85.81M | $85.81M | $85.81M | $85.81M | $85.81M | $85.81M | $85.81M | $85.81M | $85.81M | $85.81M | $85.68M | $84.24M | $22.43M | $22.68M | $1.14M | $1.14M | $1.14M | $1.14M | $1.14M |
| Intangible Assets | $14.21M | $14.48M | $14.74M | $51.90M | $53.19M | $54.48M | $55.77M | $57.07M | $58.36M | $59.74M | $61.12M | $62.49M | $63.92M | $18.26M | $18.56M | $203.00K | $256.00K | $307.00K | $356.00K | $407.00K |
| Goodwill and Intangible Assets | $100.03M | $100.29M | $100.55M | $137.71M | $139.00M | $140.29M | $141.59M | $142.88M | $144.17M | $145.55M | $146.93M | $148.17M | $148.16M | $40.70M | $41.24M | $1.34M | $1.39M | $1.45M | $1.49M | $1.54M |
| Long Term Investments | $- | $- | $- | $6.58M | $2.85M | $2.81M | $4.38M | $2.37M | $2.41M | $1.57M | $1.57M | $30.59M | $106.84M | $1.53M | $1.53M | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $-2.85M | $-2.81M | $-4.38M | $-2.37M | $-2.41M | $-1.57M | $-1.57M | $- | $- | $-1.53M | $-1.53M | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $6.10M | $5.91M | $8.12M | $1.68M | $8.27M | $8.49M | $10.40M | $4.57M | $5.33M | $4.96M | $3.87M | $8.47M | $9.00M | $7.67M | $5.26M | $4.98M | $4.26M | $3.40M | $3.23M | $3.00M |
| Total Non-Current Assets | $263.27M | $267.55M | $276.29M | $330.98M | $342.58M | $352.15M | $364.80M | $364.65M | $368.11M | $364.89M | $355.55M | $357.26M | $401.16M | $155.60M | $148.69M | $69.29M | $65.14M | $64.01M | $63.66M | $63.67M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $608.58M | $614.32M | $638.12M | $702.85M | $732.82M | $776.40M | $810.33M | $853.92M | $909.97M | $961.38M | $979.66M | $1.02B | $786.17M | $702.10M | $725.30M | $677.29M | $699.57M | $398.88M | $408.24M | $323.87M |
| Account Payables | $7.50M | $1.63M | $6.63M | $7.70M | $9.26M | $14.05M | $12.18M | $13.24M | $20.11M | $20.09M | $21.01M | $16.82M | $23.07M | $14.90M | $11.27M | $8.53M | $8.93M | $4.83M | $5.97M | $6.93M |
| Short Term Debt | $15.03M | $29.61M | $29.11M | $14.62M | $29.62M | $29.79M | $26.26M | $26.79M | $28.45M | $27.28M | $28.70M | $28.33M | $25.37M | $17.98M | $17.45M | $16.20M | $16.22M | $16.15M | $16.67M | $18.89M |
| Tax Payables | $3.27M | $2.73M | $2.34M | $2.10M | $3.20M | $4.37M | $6.39M | $5.19M | $3.76M | $3.66M | $3.85M | $3.59M | $3.17M | $2.44M | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $2.13M | $2.94M | $2.54M | $2.64M | $36.57M | $37.59M | $1.94M | $3.68M | $3.48M | $37.20M | $- | $30.42M | $28.76M | $24.39M | $18.17M | $15.09M | $18.85M | $14.03M | $12.12M |
| Other Current Liabilities | $43.85M | $34.91M | $32.74M | $40.52M | $20.52M | $25.11M | $27.99M | $26.89M | $27.83M | $36.15M | $39.12M | $35.90M | $28.43M | $27.73M | $26.11M | $15.72M | $11.95M | $15.05M | $8.73M | $4.39M |
| Total Current Liabilities | $69.65M | $71.01M | $73.76M | $67.49M | $65.23M | $73.32M | $72.82M | $72.11M | $83.84M | $90.66M | $92.69M | $84.63M | $80.03M | $63.05M | $54.83M | $40.44M | $37.10M | $36.03M | $31.38M | $30.21M |
| Long Term Debt | $67.59M | $70.22M | $72.62M | $74.80M | $77.07M | $79.17M | $79.90M | $77.82M | $79.75M | $81.27M | $64.24M | $65.50M | $60.28M | $53.16M | $53.85M | $22.24M | $24.31M | $26.24M | $27.92M | $29.36M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $15.41M | $407.00K | $597.00K | $421.00K | $475.00K | $475.00K | $60.00K | $60.00K | $60.00K | $60.00K | $2.06M | $8.15M | $19.67M | $5.07M | $6.17M | $422.00K | $210.00K | $351.00K | $- | $95.00K |
| Total Non-Current Liabilities | $82.99M | $70.63M | $73.22M | $75.22M | $77.55M | $79.65M | $79.96M | $77.88M | $79.81M | $81.33M | $66.30M | $73.64M | $79.95M | $58.22M | $60.02M | $22.67M | $24.52M | $26.59M | $27.92M | $29.46M |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $152.64M | $141.63M | $146.98M | $142.72M | $142.77M | $152.97M | $152.78M | $149.99M | $163.65M | $171.99M | $158.99M | $158.28M | $159.99M | $121.28M | $114.85M | $63.11M | $61.62M | $62.62M | $59.29M | $59.67M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $- | $- | $- | $560.13M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Retained Earnings | $-1.27B | $- | $-1.21B | $-1.12B | $-1.08B | $-1.03B | $-986.79M | $-929.40M | $-870.24M | $-828.42M | $-777.30M | $-716.78M | $-656.12M | $-610.55M | $-569.31M | $-529.27M | $-491.36M | $-458.45M | $-434.14M | $-405.93M |
| Accumulated Other Comprehensive Income Loss | $-649.00K | $-522.00K | $-735.00K | $-660.00K | $-565.00K | $-756.00K | $-635.00K | $111.00K | $-609.00K | $-1.84M | $-1.38M | $-475.00K | $363.00K | $546.00K | $428.00K | $190.00K | $142.00K | $87.00K | $134.00K | $213.00K |
| Other Total Stockholders Equity | $1.73B | $473.21M | $1.70B | $1.68B | $1.67B | $1.66B | $1.64B | $1.63B | $1.62B | $1.62B | $1.60B | $1.58B | $1.28B | $1.19B | $1.18B | $1.14B | $1.13B | $794.63M | $782.95M | $669.92M |
| Total Stockholders Equity | $455.94M | $472.69M | $491.14M | $560.13M | $590.04M | $623.43M | $657.55M | $703.93M | $746.33M | $789.38M | $820.68M | $863.36M | $626.18M | $580.82M | $610.45M | $614.18M | $637.95M | $336.26M | $348.95M | $264.20M |
| Total Equity | $455.94M | $472.69M | $491.14M | $560.13M | $590.04M | $623.43M | $657.55M | $703.93M | $746.33M | $789.38M | $820.68M | $863.36M | $626.18M | $580.82M | $610.45M | $614.18M | $637.95M | $336.26M | $348.95M | $264.20M |
| Total Liabilities and Stockholders Equity | $608.58M | $614.32M | $638.12M | $702.85M | $732.82M | $776.40M | $810.33M | $853.92M | $909.97M | $961.38M | $979.66M | $1.02B | $786.17M | $702.10M | $725.30M | $677.29M | $699.57M | $398.88M | $408.24M | $323.87M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $608.58M | $614.32M | $638.12M | $702.85M | $732.82M | $776.40M | $810.33M | $853.92M | $909.97M | $961.38M | $979.66M | $1.02B | $786.17M | $702.10M | $725.30M | $677.29M | $699.57M | $398.88M | $408.24M | $323.87M |
| Total Investments | $49.42M | $50.08M | $50.28M | $56.57M | $44.88M | $49.94M | $49.69M | $72.46M | $122.03M | $126.28M | $151.34M | $196.82M | $217.08M | $12.03M | $44.13M | $156.33M | $238.50M | $196.34M | $103.91M | $45.67M |
| Total Debt | $82.62M | $85.03M | $87.18M | $89.42M | $91.88M | $94.07M | $93.03M | $91.22M | $93.97M | $94.91M | $78.60M | $79.66M | $72.97M | $62.92M | $63.76M | $31.93M | $34.08M | $35.98M | $37.92M | $40.48M |
| Net Debt | $-138.79M | $-141.29M | $-151.96M | $-153.92M | $-174.39M | $-192.40M | $-214.43M | $-223.98M | $-222.71M | $-283.77M | $-297.65M | $-327.96M | $-118.66M | $-402.91M | $-411.52M | $-367.40M | $-314.71M | $-57.69M | $-169.93M | $-143.92M |
Annual Cash Flow
| Breakdown | September 30, 2024 | September 30, 2023 | September 30, 2022 | September 30, 2021 | September 30, 2020 |
|---|---|---|---|---|---|
| Net Income | $-208.73M | $-204.62M | $-217.86M | $-152.10M | $-139.93M |
| Depreciation and Amortization | $31.43M | $29.31M | $16.51M | $9.75M | $6.68M |
| Deferred Income Tax | $- | $-410.00K | $- | $630.00K | $-214.00K |
| Stock Based Compensation | $50.92M | $30.28M | $79.66M | $37.00M | $17.10M |
| Change in Working Capital | $15.41M | $-1.01M | $-5.36M | $-9.38M | $-25.18M |
| Accounts Receivables | $8.44M | $-4.32M | $-9.62M | $-2.20M | $-14.27M |
| Inventory | $7.99M | $7.24M | $-7.54M | $-19.49M | $-4.96M |
| Accounts Payables | $-11.80M | $-2.51M | $7.38M | $8.54M | $-5.51M |
| Other Working Capital | $10.79M | $-1.42M | $4.42M | $3.77M | $-442.00K |
| Other Non Cash Items | $46.86M | $3.98M | $2.66M | $1.86M | $-707.00K |
| Net Cash Provided by Operating Activities | $-64.09M | $-142.47M | $-124.39M | $-112.24M | $-142.25M |
| Investments in Property Plant and Equipment | $-5.08M | $-27.78M | $-101.86M | $-27.06M | $-9.87M |
| Acquisitions Net | $- | $5.86M | $-8.16M | $-483.00K | $104.78M |
| Purchases of Investments | $-51.91M | $-76.34M | $-217.64M | $-58.80M | $-202.88M |
| Sales Maturities of Investments | $53.91M | $154.74M | $100.48M | $242.49M | $98.10M |
| Other Investing Activities | $- | $-5.86M | $-5.75M | $183.70M | $-104.78M |
| Net Cash Used for Investing Activities | $-3.07M | $50.61M | $-232.93M | $156.16M | $-114.65M |
| Debt Repayment | $- | $- | $-1.56M | $-3.33M | $-3.33M |
| Common Stock Issued | $- | $- | $269.82M | $323.86M | $295.56M |
| Common Stock Repurchased | $-3.98M | $-4.41M | $-7.75M | $-10.85M | $-2.42M |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $10.87M | $5.32M | $10.02M | $19.50M | $13.92M |
| Net Cash Used Provided by Financing Activities | $6.89M | $911.00K | $270.53M | $329.18M | $303.73M |
| Effect of Forex Changes on Cash | $126.00K | $-27.00K | $-319.00K | $20.00K | $21.00K |
| Net Change in Cash | $-60.15M | $-90.98M | $-87.10M | $373.11M | $46.85M |
| Cash at End of Period | $229.13M | $289.28M | $380.26M | $467.36M | $94.25M |
| Cash at Beginning of Period | $289.28M | $380.26M | $467.36M | $94.25M | $47.40M |
| Operating Cash Flow | $-64.09M | $-142.47M | $-124.39M | $-112.24M | $-142.25M |
| Capital Expenditure | $-5.08M | $-27.78M | $-101.86M | $-27.06M | $-9.87M |
| Free Cash Flow | $-69.17M | $-170.25M | $-226.24M | $-139.31M | $-152.12M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-31.59M | $-34.66M | $-85.57M | $-45.49M | $-43.01M | $-46.24M | $-57.40M | $-59.16M | $-41.82M | $-51.12M | $-60.52M | $-60.67M | $-45.56M | $-41.24M | $-40.04M | $-37.92M | $-32.90M | $-24.32M | $-28.21M | $-31.77M |
| Depreciation and Amortization | $6.38M | $6.66M | $8.30M | $8.30M | $8.17M | $8.50M | $8.49M | $7.03M | $5.29M | $4.95M | $4.44M | $3.97M | $3.15M | $2.43M | $2.74M | $2.46M | $2.11M | $1.89M | $1.72M | $1.56M |
| Deferred Income Tax | $- | $- | $- | $345.00K | $- | $221.00K | $3.62M | $-676.00K | $- | $11.18M | $-132.00K | $-500.00K | $-10.54M | $-51.00K | $-48.00K | $605.00K | $124.00K | $29.00K | $-11.00K | $-82.00K |
| Stock Based Compensation | $11.99M | $12.35M | $13.73M | $13.82M | $11.02M | $11.75M | $10.60M | $10.26M | $-2.33M | $19.05M | $20.04M | $22.46M | $18.11M | $9.25M | $9.18M | $11.55M | $7.02M | $5.13M | $4.07M | $4.20M |
| Change in Working Capital | $-8.19M | $-1.14M | $12.56M | $3.46M | $532.00K | $441.00K | $12.02M | $-1.85M | $-11.62M | $2.52M | $4.98M | $-2.32M | $-10.55M | $-3.99M | $-2.54M | $-1.26M | $-1.59M | $-8.20M | $-111.00K | $-32.20M |
| Accounts Receivables | $-4.54M | $-2.95M | $4.00M | $-657.00K | $8.06M | $-1.81M | $5.54M | $-3.95M | $-4.10M | $662.00K | $-6.44M | $-1.81M | $-2.03M | $-290.00K | $-581.00K | $-2.21M | $884.00K | $-13.03M | $1.48M | $-1.78M |
| Inventory | $560.00K | $4.41M | $1.89M | $486.00K | $1.20M | $4.29M | $3.56M | $4.67M | $-5.28M | $3.70M | $1.55M | $-4.35M | $-8.44M | $-10.57M | $-5.37M | $-2.42M | $-1.12M | $875.00K | $-2.40M | $-3.35M |
| Accounts Payables | $5.71M | $-4.88M | $-1.20M | $-1.52M | $-4.21M | $1.92M | $-220.00K | $-7.49M | $3.28M | $6.92M | $1.23M | $-757.00K | $-5.00K | $3.35M | $1.40M | $339.00K | $3.46M | $-1.69M | $-740.00K | $-2.52M |
| Other Working Capital | $-9.92M | $2.28M | $7.88M | $5.15M | $-4.52M | $-3.96M | $3.14M | $4.92M | $-5.52M | $-8.76M | $6.17M | $4.60M | $-73.00K | $3.53M | $2.01M | $3.04M | $-4.81M | $5.65M | $1.54M | $-24.56M |
| Other Non Cash Items | $-20.00K | $1.47M | $44.60M | $32.60M | $312.00K | $4.63M | $-739.00K | $103.00K | $-3.59M | $12.15M | $-3.25M | $-5.29M | $-1.26M | $-1.20M | $2.75M | $8.00K | $303.00K | $262.00K | $-934.00K | $-373.00K |
| Net Cash Provided by Operating Activities | $-21.43M | $-15.32M | $-6.38M | $-19.42M | $-22.97M | $-20.70M | $-23.41M | $-44.29M | $-54.07M | $-1.27M | $-34.12M | $-42.34M | $-46.65M | $-34.80M | $-27.96M | $-24.55M | $-24.93M | $-25.20M | $-23.47M | $-58.67M |
| Investments in Property Plant and Equipment | $-2.27M | $-2.00M | $-965.00K | $-603.00K | $-1.51M | $-2.39M | $-4.51M | $-9.05M | $-11.82M | $-16.46M | $-40.64M | $-31.97M | $-12.78M | $-8.09M | $-6.94M | $-8.40M | $-3.63M | $-2.23M | $-2.85M | $-2.74M |
| Acquisitions Net | $- | $- | $- | $- | $- | $-212.79M | $-23.18M | $-50.21M | $218.65M | $-5.75M | $- | $- | $-8.16M | $-483.00K | $-151.70M | $- | $-32.00M | $- | $- | $- |
| Purchases of Investments | $-20.59M | $-21.19M | $-1.75M | $-10.64M | $-18.33M | $-18.09M | $-7.82M | $-27.79M | $-22.65M | $- | $- | $- | $-217.64M | $58.80M | $-58.80M | $15.50M | $-74.29M | $-92.44M | $-103.90M | $- |
| Sales Maturities of Investments | $21.32M | $21.91M | $2.00M | $6.00M | $24.00M | $18.24M | $31.00M | $78.00M | $27.50M | $25.00M | $44.80M | $18.68M | $12.00M | $32.00M | $112.00M | $66.49M | $32.00M | $- | $45.60M | $31.50M |
| Other Investing Activities | $- | $- | $- | $-4.64M | $5.67M | $212.79M | $23.18M | $50.21M | $-218.65M | $-5.75M | $44.80M | $18.68M | $-205.64M | $-58.31M | $210.01M | $81.99M | $32.00M | $-92.44M | $-58.30M | $31.50M |
| Net Cash Used for Investing Activities | $-1.54M | $-1.28M | $-711.00K | $-5.24M | $4.17M | $-2.25M | $18.67M | $41.16M | $-6.97M | $2.78M | $4.16M | $-13.29M | $-226.58M | $23.91M | $104.58M | $73.59M | $-45.92M | $-94.67M | $-61.15M | $28.76M |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-1.56M | $-833.00K | $-833.00K | $-834.00K | $-833.00K | $-833.00K | $-833.00K | $-834.00K |
| Common Stock Issued | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-2.00K | $6.00K | $269.82M | $- | $- | $-26.00K | $-193.00K | $324.08M | $-244.00K | $107.43M | $186.35M |
| Common Stock Repurchased | $-6.00K | $-8.00K | $-7.00K | $-1.54M | $-2.42M | $-1.13M | $-1.01M | $-1.26M | $-999.00K | $-1.62M | $-2.08M | $-1.49M | $-2.56M | $-2.62M | $-2.48M | $-3.34M | $-2.41M | $-773.00K | $-450.00K | $-390.00K |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-72.51M | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $17.95M | $3.63M | $2.92M | $3.36M | $951.00K | $1.57M | $353.00K | $2.79M | $604.00K | $2.87M | $763.00K | $3.29M | $3.10M | $5.03M | $2.57M | $5.82M | $6.08M | $7.42M | $1.92M | $2.91M |
| Net Cash Used Provided by Financing Activities | $17.94M | $3.63M | $2.91M | $1.83M | $-1.47M | $442.00K | $-661.00K | $1.52M | $-395.00K | $1.24M | $-1.31M | $271.62M | $-1.01M | $1.57M | $-765.00K | $1.45M | $326.92M | $5.57M | $108.06M | $188.04M |
| Effect of Forex Changes on Cash | $-53.00K | $73.00K | $2.00K | $-65.00K | $116.00K | $-48.00K | $-320.00K | $73.00K | $268.00K | $-318.00K | $-105.00K | $21.00K | $83.00K | $-133.00K | $100.00K | $48.00K | $5.00K | $27.00K | $12.00K | $-27.00K |
| Net Change in Cash | $-5.07M | $-12.90M | $-4.18M | $-22.92M | $-20.16M | $-22.56M | $-5.72M | $-1.53M | $-61.17M | $2.44M | $-31.38M | $216.00M | $-274.16M | $-9.45M | $75.95M | $50.54M | $256.07M | $-114.27M | $23.46M | $158.10M |
| Cash at End of Period | $224.06M | $229.13M | $242.04M | $243.35M | $269.12M | $289.28M | $311.84M | $317.56M | $319.09M | $380.26M | $377.82M | $409.20M | $193.20M | $467.36M | $476.81M | $400.86M | $350.32M | $94.25M | $208.52M | $185.06M |
| Cash at Beginning of Period | $229.13M | $242.04M | $246.22M | $266.27M | $289.28M | $311.84M | $317.56M | $319.09M | $380.26M | $377.82M | $409.20M | $193.20M | $467.36M | $476.81M | $400.86M | $350.32M | $94.25M | $208.52M | $185.06M | $26.95M |
| Operating Cash Flow | $-21.43M | $-15.32M | $-6.38M | $-19.42M | $-22.97M | $-20.70M | $-23.41M | $-44.29M | $-54.07M | $-1.27M | $-34.12M | $-42.34M | $-46.65M | $-34.80M | $-27.96M | $-24.55M | $-24.93M | $-25.20M | $-23.47M | $-58.67M |
| Capital Expenditure | $-2.27M | $-2.00M | $-965.00K | $-603.00K | $-1.51M | $-2.39M | $-4.51M | $-9.05M | $-11.82M | $-16.46M | $-40.64M | $-31.97M | $-12.78M | $-8.09M | $-6.94M | $-8.40M | $-3.63M | $-2.23M | $-2.85M | $-2.74M |
| Free Cash Flow | $-23.70M | $-17.32M | $-7.34M | $-20.03M | $-24.48M | $-23.10M | $-27.92M | $-53.34M | $-65.89M | $-17.73M | $-74.77M | $-74.31M | $-59.44M | $-42.89M | $-34.90M | $-32.95M | $-28.56M | $-27.43M | $-26.32M | $-61.41M |
Twist Bioscience Dividends
Explore Twist Bioscience's dividend history, including dividend yield, payout ratio, and historical payments.
Twist Bioscience News
Read the latest news about Twist Bioscience, including recent articles, headlines, and updates.
Twist Bioscience Offers Clonal Genes for Global Academic Researchers at Express Speed for No Extra Cost
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that, for a limited time, all Twist Express Genes orders placed by academic customers globally will be shipped in as few as four days* without incurring a premium for the rapid turnaround time. “At Twist, we recognize the increasing challenge within colleges, universities and research ins.
Twist Bioscience: Valuation Is Weighing On The Stock
Twist Bioscience reported solid Q1 FY25 results, although this was insufficient to drive the company's share price higher. The demand environment remains challenging, and Trump's election has created additional uncertainty. The implementation of tariffs could actually be a tailwind for Twist, though. Express genes and NGS appear to be driving Twist's growth at the moment, and this seems likely to persist for the foreseeable future.
Twist Bioscience Corporation (TWST) Q1 2025 Earnings Call Transcript
Twist Bioscience Corporation (NASDAQ:TWST ) Q1 2025 Earnings Conference Call February 3, 2025 8:00 AM ET Company Participants Angela Bitting - Senior Vice President of Corporate Affairs Emily Leproust - Chief Executive Officer and Co-Founder Patrick Finn - President and Chief Operating Officer Adam Laponis - Chief Financial Officer Conference Call Participants Matthew Sykes - Goldman Sachs Luke Sergott - Barclays Subbu Nambi - Guggenheim Securities Catherine Schulte - Baird Brendan Smith - TD Cowen Vijay Kumar - Evercore ISI Matt Larew - William Blair Puneet Souda - Leerink Partners Doug Schenkel - Wolfe Research Sung-Ji Nam - Scotiabank Operator Good day. Thank you for standing by.
Twist Bioscience Announces Fiscal 2025 First Quarter Financial Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced financial results and business highlights for the first quarter fiscal 2025 ended December 31, 2024. Visit the Events and Presentations page of the Investor Relations section under the “Company” tab at www.twistbioscience.com to view the detailed fiscal first quarter 2025 earnings report.
Gene Synthesis Market Size to Surpass USD 9.54 Billion by 2033 | Straits Research
The global gene synthesis market size was valued at USD 2.20 billion in 2024 and is projected to reach from USD 2.55 billion in 2025 to USD 9.54 billion by 2033, growing at a CAGR of 15.8% during the forecast period (2025-2033). The global gene synthesis market size was valued at USD 2.20 billion in 2024 and is projected to reach from USD 2.55 billion in 2025 to USD 9.54 billion by 2033, growing at a CAGR of 15.8% during the forecast period (2025-2033).
Twist Bioscience to Present at 43rd Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 5:15 p.m. Pacific Time in San Francisco, California. The presentation will be webcast live and can be accessed by visiting the “I.
Twist Bioscience (TWST) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for Twist Bioscience (TWST), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Twist Bioscience: Path To Profitability Beginning To Take Shape
Twist Bioscience's SynBio and NGS segments continue to generate strong growth, despite macro challenges. The prospects of the biopharma segment are uncertain, highlighted by the sale of milestones and royalties to XOMA for a small amount. Twist's margins continue to improve, and the company now appears to be on a path to cash flow breakeven over the next few years.
Twist Bioscience: A Post-Earnings Assessment
Twist Biosciences just posted a solid Q4, which had the stock rising in trading Monday. However, despite impressive sales growth, Twist Biosciences remains unprofitable, with projected losses for several years even as revenues rise. The company does have a solid balance sheet and north of $1.2 billion in net loss carry forwards.
Twist Bioscience Corporation (TWST) Q4 2024 Earnings Call Transcript
Twist Bioscience Corporation (NASDAQ:TWST ) Q4 2024 Earnings Conference Call November 18, 2024 8:00 AM ET Company Participants Angela Bitting - SVP, Corporate Affairs Emily Leproust - CEO and Co-Founder Adam Laponis - CFO Patrick Finn - President and COO Conference Call Participants Matt Sykes - Goldman Sachs Vijay Kumar - Evercore ISI Sung-Ji Nam - Scotiabank Subbu Nambi - Guggenheim Securities Luke Sergott - Barclays Matt Larew - William Blair Puneet Souda - Leerink Partners Tom Peterson - Baird Chad Wiatrowski - TD Cowen Thomas DeBourcy - Nephron Research Rachel Vatnsdal - JPMorgan Operator Welcome to Twist Bioscience's 2024 Fourth Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Twist Bioscience Announces Fiscal 2024 Fourth Quarter and Full Year Financial Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced financial results and business highlights for the fourth quarter and full year fiscal 2024 ended September 30, 2024. Visit the Events and Presentations page of the Investor Relations section under the “Company” tab at www.twistbioscience.com to view the detailed fiscal fourth quarter and.
Twist Bioscience's Earnings Preview: Partnerships And Valuation Make It A 'Buy'
Since I last covered it, Twist Bioscience has made significant strides. They have secured new partnerships, launched innovative products, and secured strategic financial agreements. TWST's valuation multiples now appear more reasonable, making it a compelling buy for new investors, with a long cash runway and potential self-sustainability by 2025-2026. The company has improved its gross margins and reduced EBIT margins, signaling rapid margin improvement and benefiting from economies of scale.
Twist Bioscience Launches FlexPrep™ Ultra-High Throughput Library Preparation Kit for Applications in Agrigenomics and Population Genomics
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of the FlexPrep™ Ultra-High Throughput Library Preparation Kit, designed with a proprietary Twist-developed enzyme to enable throughput at a low cost, and accelerate the adoption of NGS by microarray users in population and agricultural genomics (agrigenomics).
Twist Bioscience to Present at Baird Global Healthcare Conference 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the Baird Global Healthcare Conference 2024 in New York City on Tuesday, September 10 at 2:35 p.m. Eastern Time. The presentation will be webcast live and can be accessed by visiting the “I.
3 Healthcare AI Stocks Positioned for Potential Breakthroughs
Markets tanked on Monday because the Japanese central bank raised its interest rate to 0.25%. Interest rates were originally at a benchmark between 0 and 0.1, meaning a minor 15- to 25-basis-point increase had significant consequences for investors who were making margin calls with Yen.
The 3 Best Med Tech Stocks to Buy Now
According to the Advanced Medical Technology Association, med tech is defined as “companies that develop, manufacture, and distribute the technologies, devices, equipment, diagnostic tests, and health information systems.” The organization reports that these firms favorably change health care with “earlier disease detection, less-invasive procedures, and more effective treatments.
Twist Bioscience: Lowered Biopharma Expectations Amid Financial Strain (Rating Downgrade)
Twist Bioscience reported revenue of $81.5 million in Q2 (fiscal Q3), marking a 28% increase from Q2, 2023. Twist's biopharma segment underperformed, contributing to a significant impairment charge. The company's future relies on its synthetic biology segment, facing competition and uncertain prospects in a rapidly evolving market.
Twist Bioscience Corporation (TWST) Q3 2024 Earnings Call Transcript
Twist Bioscience Corporation (NASDAQ:TWST ) Q3 2024 Earnings Conference Call August 2, 2024 8:00 AM ET Company Participants Angela Bitting - Senior Vice President, Corporate Affairs Emily Leproust - Chief Executive Officer & Co-Founder Adam Laponis - Chief Financial Officer Patrick Finn - President and COO Conference Call Participants Steven Mah - Cowen Matt Larew - William Blair Luke Sergott - Barclays Vijay Kumar - Evercore ISI Sung-Ji Nam - Scotiabank Subbu Nambi - Guggenheim Securities Puneet Souda - Leerink Partners Tom Peterson - Baird Thomas DeBourcy - Nephron Research Operator Good day, and thank you for standing by. Welcome to Twist Bioscience Fiscal 2024 Third Quarter Financial Results Conference Call.
Twist Bioscience Reports Fiscal Third Quarter 2024 Financial Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the third quarter of fiscal 2024 ended June 30, 2024. "We once again surpassed our revenue guidance, ending the quarter with $81.5 million in revenue, and exceeded our targets for both cash burn and gross margin," said Emily M.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for TWST.